Donor Selection

Aplastic anemia is a bone marrow failure process that presents with pancytopenia and bone marrow hypoplasia/aplasia.

Most patients who receive a pacemaker are likely not thinking about its potential usefulness after their death; however, a viable, properly reconditioned device could help meet an overwhelming need outside of the United States.

Despite an expanded availability of donor hearts, there remains a shortage of available donor organs for people in need of transplantation, and many experts point to widespread inefficiencies with the U.S. organ transplant system.

Data show 6-month survival after transplantation with a donor heart reanimated with extracorporeal nonischemic perfusion after circulatory death was similar to 6-month survival after transplantation of a donor heart after brain death.

Adults who received heart transplants from SARS-CoV-2-positive donors experienced similar 30-day and 1-year outcomes compared with recipients of SARS-CoV-2-negative hearts, according to a registry analysis.

Donor hearts that meet U.S. Public Health Services increased risk criteria are used much more frequently in adults than in children despite similar posttransplant patient survival and an ongoing organ donor shortage, researchers reported.

Kidney transplant recipients experience immune-insufficiency during acute COVID-19, which may explain the low rates of acute rejection among these patients even with reduced immunosuppression, according to a recently published study.

A man who became the first in the world to receive a genetically modified pig’s heart has died 2 months after the procedure, according to a press release.

Recipients of hearts donated after circulatory death had similar outcomes to recipients of hearts donated after brain death, researchers reported.

Having a first-degree relative with a history of end-stage kidney disease did not appear to increase the risk for long-term kidney function decline or hypertension in African American kidney donors, according to study results.